Researchers discovered the vulnerability of cats and ferrets to SARS while searching for animals to test potential vaccines. But we still do not know if the animals can pass the virus to people. Although reports have stated that at this time, pet owners should be alarmed, there are two disturbing factors:
By utilising a proven 100% natural methodology called the HealthRestore programme. The HealthRestore programme is based on Natural dietary principles, system cleansing+ natural supplementation, and addresses issues of system toxicity and Ph imbalance problems.
IAS Congress delegates surveyed today by Axios Group, specialists in chronic disease management and drug delivery, overwhelmingly agreed that the cost of HIV treatments is not the reason why few patients are being treated in developing countries; the multiple inadequacies of the healthcare systems are the problem.
Here are some steps you can take to protect yourself and your family from Lyme disease at this critical time of the year. According to the Centers for Disease Control and Prevention, most cases of Lyme disease are reported in June through August (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5102a3.htm).
The Fluoroquinolone Toxicity Research Foundation continues to collect post-marketing reports regarding the non-abating nature of the severe and crippling (and at times fatal) adverse drug reactions associated with fluoroquinolone therapy via the Internet. Since one of the first such forums went on line back in 1999, over five years worth of horror stories regarding the damage these drugs can and will do have been forwarded to the FDA. In spite of the overwhelming evidence of such severe and at times fatal adverse reactions, the FDA continues to refuse to take action. In a recent letter received from the FDA, Frances T. Gipson, FACHE Office of Executive Programs Center for Drug Evaluation and Research, states that "we will weigh all risks and benefits associated with Fluoroquinolone Class Drugs prior to taking any additional action? We will continue to monitor future adverse events reported to us." To add insult to injury regarding such inaction by the FDA, Gipson also states "It was also noted that the majority of those adverse events reported are well-known side effects of the Fluoroquinolone class of drugs"
FACES (Friends And Caregivers, Encephalitis Survivors) represents a strong and dedicated group of people striving to share information and support, and to raise awareness on the topic of encephalitis. Previous Conferences held in Ottawa Canada, and Las Vegas Nevada, welcomed survivors, caregivers and loved ones from India and Great Britain, as well as Canada and the United States.
Every year the economic and healthcare burdens from flu and cold illnesses are tremendous. Now we are confronted with the rapid spread of highly pathogenic avian influenza in several areas in Asia. Health officials around the world are now closely monitoring the spread of avian influenza and particularly officials in Asian countries are sounding alarms to warn the general populations that the so-called "bird flu" presents a risk of evolving into an efficient and dangerous human pathogen. The possible pandemic could be a threat to human health and a disaster for agricultural production.
January 28 2004--Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that f HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world?s population.
Scope
Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population
Overview of the limitations surrounding co-morbid management such as recognition of co
infection, high-risk groups and lack of efficacious antivirals
Report Highlights
Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing
the lifespan of this co-morbid population. Effective treatment is currently hampered by
poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines.
Reasons to Purchase
Effectively target this niche sector, through a complete understanding of the prevalence
of the co-morbid population in the seven major markets
Identify the most promising products in the HIV and HBV pipelines, and track how current
players are seeking to optimize their market share
For a complete index of this report click on
http://www.researchandmarkets.com/reports/42806
About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute
thousands of major research publications from the world's leading publishers, consultants
and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or
mailto:press@researchandmarkets.com-----
EXTENDED BODY:
Research and Markets are delighted to announce the addition of Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy to their offering - 2004-01-28-----
--------
As the size of the online consumer audience continues to expand, it is important for pharmaceutical companies to create websites that attract, convert and retain as many consumers as possible. This PowerPoint trend analysis pack contains a guide to identifying specific consumer groups and to presenting information to meet consumers needs while enhancing pharmaceutical company brand recognition.
QHR's Materiel Resource Group ("QMRG"), has developed a Strategic Value Management Program? using value management analytical expertise and proprietary software developed by The HCP Group, Ltd. ("HCP"), of Skippack, PA. This program will provide QHR's healthcare clients with supply chain savings "beyond price discounts" through better supply/value chain management utilizing the tools and techniques of value analysis. Specifically, the program analyzes supply-value chain expenses and identifies savings opportunities in several supply/value chain management categories.